Get the latest news, insights, and market updates on AKTX (Akari Therapeutics, Plc). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling WorkTAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced the initiation of GMP manufacturing activities to support the development of AKTX-101, the Company’s lead ADC program. Akari has selected WuXi XDC, the world’s leading ADC contract development and Dec 23, 2025 - $AKTX
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Watch the “What This Means” video here TAMPA, Fla. and LONDON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor "What This Means" segment. As part of the segment, Mr. Gaslightwala discussed the Company’s novel spliceosome modulating payload, PH1, and Akari’s ongoing Dec 18, 2025 - $AKTX
Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
New cash portion of offering includes >20% participation from Directors, Officers and Executive ManagementTAMPA, Fla. and LONDON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 12,607,487 of the Company’s American Depositary Shares (“ADSs”) or ADS equivalen Dec 16, 2025 - $AKTX
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates The K-Ras G12V mutation is the oncogenic driver for 1/3 of all pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer Significant unmet need in pancreatic cancer where median overall survival (OS) is 1.4 years1 TAMPA, Fla. and LONDON, Dec. 09, 2025 (GLOBE NEW Dec 9, 2025 - $AKTX
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple